Compare Inovio Pharmaceuticals Inc (INO) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Teucrium Soybean Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Teucrium Soybean Fund trades at $25.05. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SOYB | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $26.28 |
52-Week Low | $0.66 | $21.46 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
SOYB trades at $25.05, down 0.48% on the day, with a bearish technical bias from moving averages and neutral oscillators. Key support and resistance cluster at $25. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights agricultural sector volatility from geopolitical tensions and trade developments.
The outlook is clouded by missing financial data, though China's $17 billion U.S. crop purchase pledge through 2028 (Zacks Investment Research, 2026-05-18) offers potential tailwinds. Risks include commodity price swings from Middle East conflicts (24/7 Wall Street, 2026-07-24) and opaque company performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
